25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Tarsus Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Tarsus Pharmaceuticals Inc together

I guess you are interested in Tarsus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Tarsus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Tarsus Pharmaceuticals Inc

I send you an email if I find something interesting about Tarsus Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Tarsus Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Tarsus Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.63
Expected worth in 1 year
$9.38
How sure are you?
36.8%

+ What do you gain per year?

Total Gains per Share
$2.75
Return On Investment
8.5%

For what price can you sell your share?

Current Price per Share
$32.29
Expected price per share
$29.21 - $42.50
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Tarsus Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$32.29
Intrinsic Value Per Share
$-59.03 - $-70.25
Total Value Per Share
$-52.40 - $-63.62

2.2. Growth of Tarsus Pharmaceuticals Inc (5 min.)




Is Tarsus Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$252.2m$179.1m$55.3m23.6%

How much money is Tarsus Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$37.5m-$22.2m-$15.2m-40.8%
Net Profit Margin-655.9%-303.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Tarsus Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#218 / 960

Most Revenue
#217 / 960

Most Profit
#809 / 960

Most Efficient
#677 / 960
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Tarsus Pharmaceuticals Inc?

Welcome investor! Tarsus Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Tarsus Pharmaceuticals Inc.

First you should know what it really means to hold a share of Tarsus Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Tarsus Pharmaceuticals Inc is $32.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tarsus Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tarsus Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.63. Based on the TTM, the Book Value Change Per Share is $0.69 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.48 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tarsus Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.88-2.7%-0.99-3.1%-0.60-1.9%-0.43-1.3%-0.43-1.3%
Usd Book Value Change Per Share-0.60-1.9%0.692.1%-0.48-1.5%0.351.1%0.351.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.60-1.9%0.692.1%-0.48-1.5%0.351.1%0.351.1%
Usd Price Per Share27.18-25.39-15.61-18.00-18.00-
Price to Earnings Ratio-7.76--6.59--7.01--3.95--3.95-
Price-to-Total Gains Ratio-45.02--15.82--35.78--11.12--11.12-
Price to Book Ratio4.10-4.05-3.38-3.58-3.58-
Price-to-Total Gains Ratio-45.02--15.82--35.78--11.12--11.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share32.29
Number of shares30
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.690.35
Usd Total Gains Per Share0.690.35
Gains per Quarter (30 shares)20.6110.47
Gains per Year (30 shares)82.4241.88
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10827204232
2016515408474
302472360126116
403303180168158
504124000209200
604954820251242
705775640293284
806596460335326
907427280377368
1008248100419410

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.017.00.010.5%2.017.00.010.5%2.017.00.010.5%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%7.011.01.036.8%7.011.01.036.8%7.011.01.036.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%7.011.01.036.8%7.011.01.036.8%7.011.01.036.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Tarsus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6040.687-188%-0.485-20%0.349-273%0.349-273%
Book Value Per Share--6.6316.165+8%4.710+41%4.061+63%4.061+63%
Current Ratio--7.0318.282-15%14.794-52%18.525-62%18.525-62%
Debt To Asset Ratio--0.3310.252+31%0.173+91%0.302+9%0.302+9%
Debt To Equity Ratio--0.4940.343+44%0.211+134%0.154+220%0.154+220%
Dividend Per Share----0%-0%-0%-0%
Eps---0.875-0.986+13%-0.598-32%-0.426-51%-0.426-51%
Free Cash Flow Per Share---0.406-0.825+103%-0.504+24%-0.334-18%-0.334-18%
Free Cash Flow To Equity Per Share--0.7060.988-28%-0.466+166%0.448+58%0.448+58%
Gross Profit Margin--1.0001.135-12%1.0000%1.029-3%1.029-3%
Intrinsic Value_10Y_max---70.253--------
Intrinsic Value_10Y_min---59.032--------
Intrinsic Value_1Y_max---2.727--------
Intrinsic Value_1Y_min---2.676--------
Intrinsic Value_3Y_max---11.479--------
Intrinsic Value_3Y_min---10.893--------
Intrinsic Value_5Y_max---24.195--------
Intrinsic Value_5Y_min---22.175--------
Market Cap1228366493.000+16%1033973406.000965783658.750+7%593640728.500+74%684710556.105+51%684710556.105+51%
Net Profit Margin---0.816-6.559+704%-3.030+271%-6.964+754%-6.964+754%
Operating Margin---0.816-6.916+748%-3.373+313%-6.900+746%-6.900+746%
Operating Ratio--1.8167.865-77%3.939-54%8.859-80%8.859-80%
Pb Ratio4.870+16%4.0994.050+1%3.379+21%3.585+14%3.585+14%
Pe Ratio-9.225-19%-7.765-6.588-15%-7.015-10%-3.947-49%-3.947-49%
Price Per Share32.290+16%27.18025.388+7%15.605+74%17.999+51%17.999+51%
Price To Free Cash Flow Ratio-19.885-19%-16.739-8.974-46%-8.429-50%-7.886-53%-7.886-53%
Price To Total Gains Ratio-53.489-19%-45.024-15.822-65%-35.784-21%-11.117-75%-11.117-75%
Quick Ratio--9.6359.581+1%21.601-55%19.119-50%19.119-50%
Return On Assets---0.088-0.123+40%-0.106+20%-0.075-15%-0.075-15%
Return On Equity---0.132-0.164+25%-0.129-2%-0.082-38%-0.082-38%
Total Gains Per Share---0.6040.687-188%-0.485-20%0.349-273%0.349-273%
Usd Book Value--252246000.000234527250.000+8%179165000.000+41%154502842.105+63%154502842.105+63%
Usd Book Value Change Per Share---0.6040.687-188%-0.485-20%0.349-273%0.349-273%
Usd Book Value Per Share--6.6316.165+8%4.710+41%4.061+63%4.061+63%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.875-0.986+13%-0.598-32%-0.426-51%-0.426-51%
Usd Free Cash Flow---15442999.000-31369499.750+103%-19157750.000+24%-12714210.474-18%-12714210.474-18%
Usd Free Cash Flow Per Share---0.406-0.825+103%-0.504+24%-0.334-18%-0.334-18%
Usd Free Cash Flow To Equity Per Share--0.7060.988-28%-0.466+166%0.448+58%0.448+58%
Usd Market Cap1228366493.000+16%1033973406.000965783658.750+7%593640728.500+74%684710556.105+51%684710556.105+51%
Usd Price Per Share32.290+16%27.18025.388+7%15.605+74%17.999+51%17.999+51%
Usd Profit---33290000.000-37517750.000+13%-22224750.000-33%-16185315.789-51%-16185315.789-51%
Usd Revenue--40813000.00020843500.000+96%6944250.000+488%9683894.737+321%9683894.737+321%
Usd Total Gains Per Share---0.6040.687-188%-0.485-20%0.349-273%0.349-273%
 EOD+5 -3MRQTTM+21 -13YOY+18 -155Y+14 -2010Y+14 -20

3.3 Fundamental Score

Let's check the fundamental score of Tarsus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.225
Price to Book Ratio (EOD)Between0-14.870
Net Profit Margin (MRQ)Greater than0-0.816
Operating Margin (MRQ)Greater than0-0.816
Quick Ratio (MRQ)Greater than19.635
Current Ratio (MRQ)Greater than17.031
Debt to Asset Ratio (MRQ)Less than10.331
Debt to Equity Ratio (MRQ)Less than10.494
Return on Equity (MRQ)Greater than0.15-0.132
Return on Assets (MRQ)Greater than0.05-0.088
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Tarsus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.541
Ma 20Greater thanMa 5032.020
Ma 50Greater thanMa 10028.182
Ma 100Greater thanMa 20029.782
OpenGreater thanClose32.890
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Fundamental data was last updated by Penke on 2024-09-13 09:21:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Tarsus Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Tarsus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -81.6% means that $-0.82 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is -81.6%. The company is making a huge loss. -2
  • The TTM is -655.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-81.6%TTM-655.9%+574.4%
TTM-655.9%YOY-303.0%-353.0%
TTM-655.9%5Y-696.4%+40.4%
5Y-696.4%10Y-696.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-81.6%-126.1%+44.5%
TTM-655.9%-194.5%-461.4%
YOY-303.0%-207.8%-95.2%
5Y-696.4%-373.2%-323.2%
10Y-696.4%-473.1%-223.3%
4.3.1.2. Return on Assets

Shows how efficient Tarsus Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tarsus Pharmaceuticals Inc to the Biotechnology industry mean.
  • -8.8% Return on Assets means that Tarsus Pharmaceuticals Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is -8.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.8%TTM-12.3%+3.5%
TTM-12.3%YOY-10.6%-1.8%
TTM-12.3%5Y-7.5%-4.8%
5Y-7.5%10Y-7.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.8%-11.1%+2.3%
TTM-12.3%-11.9%-0.4%
YOY-10.6%-11.3%+0.7%
5Y-7.5%-13.2%+5.7%
10Y-7.5%-14.9%+7.4%
4.3.1.3. Return on Equity

Shows how efficient Tarsus Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tarsus Pharmaceuticals Inc to the Biotechnology industry mean.
  • -13.2% Return on Equity means Tarsus Pharmaceuticals Inc generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is -13.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.2%TTM-16.4%+3.2%
TTM-16.4%YOY-12.9%-3.5%
TTM-16.4%5Y-8.2%-8.2%
5Y-8.2%10Y-8.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-14.2%+1.0%
TTM-16.4%-16.0%-0.4%
YOY-12.9%-13.8%+0.9%
5Y-8.2%-19.1%+10.9%
10Y-8.2%-19.8%+11.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Tarsus Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Tarsus Pharmaceuticals Inc is operating .

  • Measures how much profit Tarsus Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tarsus Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -81.6% means the company generated $-0.82  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is -81.6%. The company is operating very inefficient. -2
  • The TTM is -691.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-81.6%TTM-691.6%+610.0%
TTM-691.6%YOY-337.3%-354.3%
TTM-691.6%5Y-690.0%-1.6%
5Y-690.0%10Y-690.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-81.6%-279.4%+197.8%
TTM-691.6%-329.9%-361.7%
YOY-337.3%-230.4%-106.9%
5Y-690.0%-391.8%-298.2%
10Y-690.0%-499.6%-190.4%
4.3.2.2. Operating Ratio

Measures how efficient Tarsus Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.82 means that the operating costs are $1.82 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is 1.816. The company is inefficient in keeping operating costs low. -1
  • The TTM is 7.865. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.816TTM7.865-6.049
TTM7.865YOY3.939+3.925
TTM7.8655Y8.859-0.994
5Y8.85910Y8.8590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8162.759-0.943
TTM7.8653.146+4.719
YOY3.9393.336+0.603
5Y8.8595.133+3.726
10Y8.8596.571+2.288
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Tarsus Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Tarsus Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.03 means the company has $7.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is 7.031. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.282. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.031TTM8.282-1.251
TTM8.282YOY14.794-6.511
TTM8.2825Y18.525-10.242
5Y18.52510Y18.5250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0313.806+3.225
TTM8.2824.010+4.272
YOY14.7944.719+10.075
5Y18.5255.980+12.545
10Y18.5256.318+12.207
4.4.3.2. Quick Ratio

Measures if Tarsus Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tarsus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 9.64 means the company can pay off $9.64 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is 9.635. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.581. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.635TTM9.581+0.054
TTM9.581YOY21.601-12.020
TTM9.5815Y19.119-9.538
5Y19.11910Y19.1190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.6353.346+6.289
TTM9.5813.567+6.014
YOY21.6014.698+16.903
5Y19.1195.910+13.209
10Y19.1196.500+12.619
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Tarsus Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Tarsus Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tarsus Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that Tarsus Pharmaceuticals Inc assets are financed with 33.1% credit (debt) and the remaining percentage (100% - 33.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is 0.331. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.252. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.331TTM0.252+0.079
TTM0.252YOY0.173+0.078
TTM0.2525Y0.302-0.051
5Y0.30210Y0.3020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3310.342-0.011
TTM0.2520.344-0.092
YOY0.1730.309-0.136
5Y0.3020.365-0.063
10Y0.3020.384-0.082
4.5.4.2. Debt to Equity Ratio

Measures if Tarsus Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tarsus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 49.4% means that company has $0.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tarsus Pharmaceuticals Inc:

  • The MRQ is 0.494. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.343. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.494TTM0.343+0.151
TTM0.343YOY0.211+0.131
TTM0.3435Y0.154+0.188
5Y0.15410Y0.1540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4940.393+0.101
TTM0.3430.439-0.096
YOY0.2110.372-0.161
5Y0.1540.448-0.294
10Y0.1540.489-0.335
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Tarsus Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Tarsus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -7.76 means the investor is paying $-7.76 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tarsus Pharmaceuticals Inc:

  • The EOD is -9.225. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.765. Based on the earnings, the company is expensive. -2
  • The TTM is -6.588. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.225MRQ-7.765-1.460
MRQ-7.765TTM-6.588-1.177
TTM-6.588YOY-7.015+0.426
TTM-6.5885Y-3.947-2.641
5Y-3.94710Y-3.9470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.225-2.310-6.915
MRQ-7.765-2.379-5.386
TTM-6.588-2.921-3.667
YOY-7.015-3.405-3.610
5Y-3.947-6.019+2.072
10Y-3.947-6.254+2.307
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tarsus Pharmaceuticals Inc:

  • The EOD is -19.885. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -16.739. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.974. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.885MRQ-16.739-3.147
MRQ-16.739TTM-8.974-7.765
TTM-8.974YOY-8.429-0.544
TTM-8.9745Y-7.886-1.088
5Y-7.88610Y-7.8860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-19.885-2.954-16.931
MRQ-16.739-3.175-13.564
TTM-8.974-3.483-5.491
YOY-8.429-4.594-3.835
5Y-7.886-8.064+0.178
10Y-7.886-8.708+0.822
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Tarsus Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.10 means the investor is paying $4.10 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Tarsus Pharmaceuticals Inc:

  • The EOD is 4.870. Based on the equity, the company is fair priced.
  • The MRQ is 4.099. Based on the equity, the company is fair priced.
  • The TTM is 4.050. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.870MRQ4.099+0.771
MRQ4.099TTM4.050+0.050
TTM4.050YOY3.379+0.671
TTM4.0505Y3.585+0.465
5Y3.58510Y3.5850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.8701.886+2.984
MRQ4.0991.972+2.127
TTM4.0502.201+1.849
YOY3.3792.363+1.016
5Y3.5853.551+0.034
10Y3.5854.200-0.615
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Tarsus Pharmaceuticals Inc.

4.8.1. Institutions holding Tarsus Pharmaceuticals Inc

Institutions are holding 111.2% of the shares of Tarsus Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30RTW INVESTMENTS, LLC8.97041.43634124861401454.2827
2024-06-30BlackRock Inc8.58720.002326671461403423.1477
2024-06-30Paradigm Biocapital Advisors LP6.4022.53332435416-427990-14.9469
2024-03-31Morgan Stanley - Brokerage Accounts6.3060.007239891844123022.5383
2024-06-30TANG CAPITAL MANAGEMENT LLC5.92726.2417225479700
2024-03-31COWEN AND COMPANY, LLC5.57952.9885212253021113111.0459
2024-06-30Vanguard Group Inc5.23030.00119896931630618.9269
2024-06-30Jennison Associates LLC3.89010.0258147986814893011.1899
2024-06-30Perceptive Advisors LLC3.40790.8487129641600
2024-06-30Assenagon Asset Management SA2.79540.0643106342210634220
2024-06-30State Street Corp2.43320.001192563920854929.0827
2024-06-30Ikarian Capital, LLC2.10373.7898002779000012.6711
2024-06-30Geode Capital Management, LLC2.03260.001877323514354322.7957
2024-06-30ExodusPoint Capital Management, LP1.76240.1243670459454501210.4581
2024-06-30Artisan Partners Limited Partnership1.64970.02566275781480.0236
2024-06-30Ensign Peak Advisors Inc1.56230.0295594325-133566-18.3497
2024-06-30Integral Health Asset Management, LLC1.55091.523459000000
2024-06-30Vivo Capital, LLC1.48671.4256555000
2024-06-30TCG Crossover Management, LLC1.46241.5759556317-237512-29.9198
2024-06-30Polygon Management Ltd1.31433.38985000005000011.1111
Total 74.454226.028728323640+2929626+10.3%

4.9.2. Funds holding Tarsus Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-07-31Vanguard Total Stock Mkt Idx Inv2.90460.0016110495100
2024-08-30iShares Russell 2000 ETF2.58550.037498357762320.6376
2024-07-31Invesco Small Cap Value A1.27440.2197484800285800143.6181
2024-07-31Vanguard Institutional Extnd Mkt Idx Tr1.24810.010747480729580.6269
2024-06-30Artisan Non-U.S. Small-Mid Growth Comp1.03270.244439284300
2024-06-30Artisan International Small-Mid Investor1.03270.244439284300
2024-07-31PGIM Jennison Small Company A0.93130.268935428900
2024-06-30Jennison SMid Cap Core Equity0.93130.31135428900
2024-08-30iShares Russell 2000 Growth ETF0.85560.0748325501-388-0.1191
2024-06-30Fidelity Small Cap Index0.78910.030430020487032.9856
2024-07-31APO Medical Opportunities R0.73850.8401280934170006.441
2024-07-31Delaware Ivy Small Cap Growth C0.68740.46362614845641127.5078
2024-06-30CREF Stock R10.66860.005525434000
2024-07-31State St Russell Sm/Mid CpÂź Indx NL Cl C0.66290.01332521633960018.6298
2024-07-31PGIM Jennison Health Sciences Z0.65420.328424885500
2024-06-30Jennison Health Sciences Equity0.65420.376424885500
2024-08-30iShares Biotechnology ETF0.59730.078522723000
2024-02-29MEDICAL BioHealth EUR Acc0.51660.895719652100
2024-07-31Fidelity Extended Market Index0.48090.0108182927105986.1499
2024-07-31Delaware Healthcare I0.39430.44415000000
Total 19.64024.89967471413+426914+5.7%

5.3. Insider Transactions

Insiders are holding 8.769% of the shares of Tarsus Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-18Aziz MottiwalaSELL476630.6
2024-03-18Bobak R AzamianSELL1041530.6
2024-03-18Bryan WahlSELL443630.6
2024-03-18Seshadri NeervannanSELL487930.6
2023-12-27Bobak R AzamianSELL800020.22
2023-12-20Bobak R AzamianSELL4000020.27
2023-12-20Jose M TrevejoSELL225220
2023-12-15Andrew D GoldbergBUY100018.96
2023-11-30Bryan WahlSELL835616.31
2023-11-30Dianne C WhitfieldSELL835516.31
2023-10-18Bobak R AzamianSELL800013.24
2023-10-05Jose M TrevejoSELL160418
2023-09-20Bobak R AzamianSELL800017.21
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets376,844
Total Liabilities124,598
Total Stockholder Equity252,246
 As reported
Total Liabilities 124,598
Total Stockholder Equity+ 252,246
Total Assets = 376,844

Assets

Total Assets376,844
Total Current Assets362,588
Long-term Assets14,256
Total Current Assets
Cash And Cash Equivalents 181,095
Short-term Investments 142,485
Net Receivables 30,841
Inventory 2,195
Other Current Assets 5,972
Total Current Assets  (as reported)362,588
Total Current Assets  (calculated)362,588
+/-0
Long-term Assets
Property Plant Equipment 4,210
Long Term Investments 3,000
Intangible Assets 3,667
Long-term Assets Other 3,379
Long-term Assets  (as reported)14,256
Long-term Assets  (calculated)14,256
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities51,571
Long-term Liabilities73,027
Total Stockholder Equity252,246
Total Current Liabilities
Short-term Debt 605
Accounts payable 26,653
Other Current Liabilities 24,313
Total Current Liabilities  (as reported)51,571
Total Current Liabilities  (calculated)51,571
+/-0
Long-term Liabilities
Long term Debt 71,578
Long-term Liabilities Other 1,449
Long-term Liabilities  (as reported)73,027
Long-term Liabilities  (calculated)73,027
+/-0
Total Stockholder Equity
Common Stock6
Retained Earnings -313,677
Accumulated Other Comprehensive Income -176
Other Stockholders Equity 566,093
Total Stockholder Equity (as reported)252,246
Total Stockholder Equity (calculated)252,246
+/-0
Other
Capital Stock6
Cash and Short Term Investments 323,580
Common Stock Shares Outstanding 37,823
Liabilities and Stockholders Equity 376,844
Net Debt -108,912
Net Invested Capital 323,824
Net Working Capital 311,017
Property Plant and Equipment Gross 5,808
Short Long Term Debt Total 72,183



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-06-302018-03-312017-12-31
> Total Assets 
0
0
0
0
0
0
0
58,316
0
56,239
92,185
171,972
193,954
203,450
190,412
178,907
181,483
252,828
236,465
227,863
211,214
188,927
268,332
266,224
349,278
376,844
376,844349,278266,224268,332188,927211,214227,863236,465252,828181,483178,907190,412203,450193,954171,97292,18556,239058,3160000000
   > Total Current Assets 
0
0
0
0
0
0
58,030
58,030
54,706
54,706
89,072
170,655
191,451
200,904
187,088
175,952
178,755
250,283
234,078
225,375
208,646
183,476
259,277
256,131
340,724
362,588
362,588340,724256,131259,277183,476208,646225,375234,078250,283178,755175,952187,088200,904191,451170,65589,07254,70654,70658,03058,030000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
57,952
0
53,135
86,329
168,129
156,179
176,735
183,801
171,332
175,010
245,363
169,489
71,660
65,997
106,773
226,672
224,947
193,705
181,095
181,095193,705224,947226,672106,77365,99771,660169,489245,363175,010171,332183,801176,735156,179168,12986,32953,135057,9520000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
483
291
0
57,083
145,366
135,222
71,455
20,213
2,495
104,819
142,485
142,485104,8192,49520,21371,455135,222145,36657,0830291483000000000000000
       Net Receivables 
0
0
0
0
0
0
36
36
2
2
1
20
32,446
20,157
139
92
323
620
4,012
3,582
2,918
246
6,370
17,714
31,361
30,841
30,84131,36117,7146,3702462,9183,5824,0126203239213920,15732,446201223636000000
       Other Current Assets 
0
0
0
0
0
0
20
42
1,077
1,057
2,310
2,526
2,826
4,012
3,148
-88
3,131
4,300
3,494
4,767
4,927
5,002
6,007
7,868
6,803
5,972
5,9726,8037,8686,0075,0024,9274,7673,4944,3003,131-883,1484,0122,8262,5262,3101,0571,0774220000000
   > Long-term Assets 
0
0
0
0
0
0
0
286
0
1,533
3,113
1,317
2,503
2,546
3,324
2,955
2,728
2,545
2,387
2,488
2,568
5,451
9,055
10,093
8,554
14,256
14,2568,55410,0939,0555,4512,5682,4882,3872,5452,7282,9553,3242,5462,5031,3173,1131,53302860000000
       Property Plant Equipment 
0
0
0
0
0
0
280
280
1,395
1,395
1,363
1,236
1,173
1,021
1,709
1,829
1,841
1,776
1,647
1,532
1,733
3,678
3,625
3,348
3,470
4,210
4,2103,4703,3483,6253,6781,7331,5321,6471,7761,8411,8291,7091,0211,1731,2361,3631,3951,395280280000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
169
157
371
306
322
210
631
0
3,000
3,000063121032230637115716900000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,967
3,867
3,767
3,667
3,6673,7673,8673,9670000000000000000000000
       Other Assets 
0
0
0
0
0
0
6
6
138
138
1,750
769
1,330
1,525
1,615
179
887
600
583
477
438
1,342
0
0
0
0
00001,3424384775836008871791,6151,5251,3307691,75013813866000000
> Total Liabilities 
0
0
0
0
0
0
0
64,321
0
3,872
110,014
5,992
10,722
10,979
11,270
12,177
32,286
31,323
33,838
34,963
37,810
41,198
54,668
69,236
74,067
124,598
124,59874,06769,23654,66841,19837,81034,96333,83831,32332,28612,17711,27010,97910,7225,992110,0143,872064,3210000000
   > Total Current Liabilities 
0
0
0
0
0
0
819
819
3,075
3,075
6,144
5,387
10,118
10,455
10,365
11,478
12,610
11,718
14,273
15,429
13,255
14,765
23,249
36,936
42,528
51,571
51,57142,52836,93623,24914,76513,25515,42914,27311,71812,61011,47810,36510,45510,1185,3876,1443,0753,075819819000000
       Short-term Debt 
0
0
0
0
0
0
0
64
0
111
190
282
221
1,733
1,572
1,306
809
605
572
721
703
431
423
398
585
605
6055853984234317037215726058091,3061,5721,7332212821901110640000000
       Accounts payable 
0
0
0
0
0
0
456
456
1,420
1,420
4,706
2,237
4,997
3,303
2,010
2,856
4,028
4,093
5,592
9,910
9,049
8,172
10,382
18,149
19,142
26,653
26,65319,14218,14910,3828,1729,0499,9105,5924,0934,0282,8562,0103,3034,9972,2374,7061,4201,420456456000000
       Other Current Liabilities 
0
0
0
0
0
0
0
299
0
1,544
1,248
758
4,587
5,077
6,783
11,478
7,773
7,020
8,109
4,798
3,503
14,765
23,249
18,389
22,801
24,313
24,31322,80118,38923,24914,7653,5034,7988,1097,0207,77311,4786,7835,0774,5877581,2481,54402990000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
63,502
0
797
103,870
605
604
524
905
699
19,676
19,605
19,565
19,534
24,555
26,433
31,419
32,300
31,539
73,027
73,02731,53932,30031,41926,43324,55519,53419,56519,60519,676699905524604605103,870797063,5020000000
       Other Liabilities 
0
0
0
0
0
0
0
0
53
53
86
56
148
524
150
114
71
43
40
48
0
1,826
0
0
0
0
00001,8260484043711141505241485686535300000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
100
100
1,700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001,70010010000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
-6,005
0
52,367
-17,829
165,980
183,232
192,471
179,142
166,730
149,197
221,505
202,627
192,900
173,404
147,729
213,664
196,988
275,211
252,246
252,246275,211196,988213,664147,729173,404192,900202,627221,505149,197166,730179,142192,471183,232165,980-17,82952,3670-6,0050000000
   Common Stock
0
0
0
0
0
0
2
2
2
1
2
4
4
4
4
4
4
5
5
5
5
5
5
5
6
6
66555555544444421222000000
   Retained Earnings Total Equity0000-163,606-132,182-108,763-95,164-72,653-66,910-46,672-31,821-16,124-22,469-32,84500000000000
   Accumulated Other Comprehensive Income -176-63-2-8-23-70-74-100000-266-1420-93-700-380000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
198,821
205,697
208,591
210,959
213,398
216,103
294,153
297,796
301,732
305,651
311,353
0
0
0
0
0000311,353305,651301,732297,796294,153216,103213,398210,959208,591205,697198,82100000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
27
0
63,677
77
198,821
11,885
5,407
210,959
213,398
216,103
294,153
297,796
301,732
305,651
311,353
416,421
441,641
555,655
566,093
566,093555,655441,641416,421311,353305,651301,732297,796294,153216,103213,398210,9595,40711,885198,8217763,6770270000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue17,447
Cost of Revenue-1,593
Gross Profit15,85415,854
 
Operating Income (+$)
Gross Profit15,854
Operating Expense-159,012
Operating Income-143,158-143,158
 
Operating Expense (+$)
Research Development50,312
Selling General Administrative80,328
Selling And Marketing Expenses0
Operating Expense159,012130,640
 
Net Interest Income (+$)
Interest Income9,486
Interest Expense-3,346
Other Finance Cost-297
Net Interest Income6,437
 
Pretax Income (+$)
Operating Income-143,158
Net Interest Income6,437
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-135,893-150,423
EBIT - interestExpense = -146,504
-135,184
-132,547
Interest Expense3,346
Earnings Before Interest and Taxes (EBIT)-143,158-132,547
Earnings Before Interest and Taxes (EBITDA)-142,281
 
After tax Income (+$)
Income Before Tax-135,893
Tax Provision-0
Net Income From Continuing Ops-107,590-135,893
Net Income-135,893
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses160,605
Total Other Income/Expenses Net7,265-6,437
 

Technical Analysis of Tarsus Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tarsus Pharmaceuticals Inc. The general trend of Tarsus Pharmaceuticals Inc is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tarsus Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tarsus Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 34.99 < 42.50.

The bearish price targets are: 31.30 > 30.23 > 29.21.

Tweet this
Tarsus Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tarsus Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tarsus Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tarsus Pharmaceuticals Inc. The current macd is 1.32377918.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Tarsus Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Tarsus Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Tarsus Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Tarsus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartTarsus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tarsus Pharmaceuticals Inc. The current adx is 32.26.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Tarsus Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Tarsus Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tarsus Pharmaceuticals Inc. The current sar is 34.37.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Tarsus Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tarsus Pharmaceuticals Inc. The current rsi is 55.54. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Tarsus Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartTarsus Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tarsus Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Tarsus Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Tarsus Pharmaceuticals Inc Daily Stochastic Oscillator ChartTarsus Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tarsus Pharmaceuticals Inc. The current cci is 17.61.

Tarsus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartTarsus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tarsus Pharmaceuticals Inc. The current cmo is 4.86434808.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Tarsus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartTarsus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tarsus Pharmaceuticals Inc. The current willr is -56.66316894.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Tarsus Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Tarsus Pharmaceuticals Inc Daily Williams %R ChartTarsus Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tarsus Pharmaceuticals Inc. The current atr is 1.72562994.

Tarsus Pharmaceuticals Inc Daily Average True Range (ATR) ChartTarsus Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tarsus Pharmaceuticals Inc. The current obv is 5,208,416.

Tarsus Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartTarsus Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tarsus Pharmaceuticals Inc. The current mfi is 64.30.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Tarsus Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartTarsus Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tarsus Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-05-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-06-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Tarsus Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tarsus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.541
Ma 20Greater thanMa 5032.020
Ma 50Greater thanMa 10028.182
Ma 100Greater thanMa 20029.782
OpenGreater thanClose32.890
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Tarsus Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Tarsus Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tarsus Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tarsus Pharmaceuticals Inc

I send you an email if I find something interesting about Tarsus Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Tarsus Pharmaceuticals Inc.

Receive notifications about Tarsus Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.